TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00793507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Health Care Early Intervention Project
Description: The intervention group will receive routine preventive dental care, 2 to 4 times per year depending on risk of caries. The intervention group will also receive pre-scheduling, reminders, and care coordination by the dental hygienist. The control group will receive usual care, but will not receive pre-scheduling, reminders, or care coordination by the dental hygienist. In order to determine the incidence of early childhood caries at study enrollment, both intervention and control groups will receive a standardized oral examination with an assessment of caries presence and extent on the day of enrollment, at 12 months and at 24 months after enrollment. Both children in the control group and intervention group will be referred to a dentist if found to need restorative care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Health Care Early Intervention Project
Description: The intervention group will receive routine preventive dental care, 2 to 4 times per year depending on risk of caries. The intervention group will also receive pre-scheduling, reminders, and care coordination by the dental hygienist. The control group will receive usual care, but will not receive pre-scheduling, reminders, or care coordination by the dental hygienist. In order to determine the incidence of early childhood caries at study enrollment, both intervention and control groups will receive a standardized oral examination with an assessment of caries presence and extent on the day of enrollment, at 12 months and at 24 months after enrollment. Both children in the control group and intervention group will be referred to a dentist if found to need restorative care.
Study: NCT02978196

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of 99mTc-NM-01
Description: Patient is injected with micro-dose of 99mTc-NM-01

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of 68Ga-NM-01
Description: Patient is injected with micro-dose of 68Ga-NM-01
Study: NCT03604796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Solution
Description: Rectal acetaminophen at 15 mg/kg x 4/day for three days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Infusion
Description: Loading dose of 15 mg/kg IV acetaminophen followed by a continuous infusion at a rate of 2.5 mg/kg/hr for 72 hours
Study: NCT01898039

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A2/4-1BBL melanoma vaccine
Description: On days 14, 35, 56, 77 and 98 the appropriate dose of irradiated M20/A2B cells will be injected into three adjacent sites on the upper arm or thigh, avoiding limbs where lymph node dissection had been previously performed.
Study: NCT01604642

Intervention type: OTHER
Group type: OTHER
Intervention: blood tests and muscular biopsies
Description: blood tests and muscular biopsies
Study: NCT01773460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus is given beyond progress (comparison with placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Everolimus-placebo
Description: Everolimus-placebo
Study: NCT03313297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD4017
Description: AZD4017 is a novel orally bioavailable small molecule inhibitor of 11β-HSD1 enzyme activity. It is potent and highly selective in vitro and in vivo. The half maximal inhibitory concentration (IC50) for inhibition of 11β-HSD1 activity (cortisone to cortisol conversion) is 2nM. AZD4017 is selective (\> 2000x) for 11β-HSD1 over human recombinant 11β-HSD2 and the closely-homologous enzymes 17β-hydroxysteroid dehydrogenase 1 and 17β-hydroxysteroid dehydrogenase 3 in vitro.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT00189917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE (MVA-BN)
Description: 1x10E08 TCID50, subcutaneous vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE (MVA-BN)
Description: 1x10E08 TCID50, subcutaneous vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE (MVA-BN)
Description: 1x10E08 TCID50, subcutaneous vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE (MVA-BN)
Description: 1x10E08 TCID50, subcutaneous vaccination
Study: NCT01693991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning-Making intervention (MMi)
Description: MMi and attention control sessions will take place weekly for 3 weeks at the patient's home or hospital, as the patient prefers. We will try to limit delays to no more than 1 week if needed (e.g., for recovery from treatment side-effects), but because the feasibility of this schedule is one of the research questions, if more flexibility is required we will not withdraw people from the study if the delay is longer, since a longer intervention period could be incorporated in a full-scale RCT. Dates and duration of each session will be tracked. MMi sessions will be conducted by 2 bilingual mental health professionals (nurse, social worker, or psychologist) with at least 1 year of clinical oncology experience and will be initiated within 1 week after randomization.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Empathic visitor
Description: This person will provide the basic ingredients fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic visitor will be specifically instructed to avoid initiating discussions about meaning (e.g., how the patient interprets his feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present).
Study: NCT02839330

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N1c
Description: Intramuscular (IM) administration, containing 7.5 mcg H5N1 hemagglutinin antigen (HA) + 0.25 mL MF59 (approximately 0.5 mL total volume).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N1c
Description: Intramuscular (IM) administration, containing 7.5 mcg H5N1 hemagglutinin antigen (HA) + 0.25 mL MF59 (approximately 0.5 mL total volume).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N1c
Description: Intramuscular (IM) administration, containing 7.5 mcg H5N1 hemagglutinin antigen (HA) + 0.25 mL MF59 (approximately 0.5 mL total volume).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Saline injection
Study: NCT02324426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Glutathione
Description: 200 mg GSH delivered in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
Study: NCT02217020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
Study: NCT01658527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orteronel
Description: Tak-700 will be administered until disease progression, diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.~Upon progression, patient may stay on study medication until the initiation of a new therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: Bicalutamide will be given at the standard daily dose of 50 mg PO (per os). Bicalutamide will be maintained until disease progression diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.
Study: NCT02514109

Intervention type: OTHER
Intervention: Neurological assessment and Blood sample
Description: Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS)) and 2 blood collection tubes for antibody screening

Intervention type: OTHER
Intervention: Neurological assessment and Blood sample
Description: Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS)) and 2 blood collection tubes for antibody screening
Study: NCT03751462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Purkinjemeter
Description: The Purkinjemeter will be used for assessment of IOL wobbling, tilt and decentration in patients with pseudoexfoliation syndrome or traumatic cataract
Study: NCT01302574

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: lactisole
Description: Lactisole-liquid meal: Lactisole (450 ppm) will be mixed with a liquid meal. Liquid meal only: The comparator will be the liquid meal alone.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lactisole
Description: Lactisole-liquid meal: Lactisole (450 ppm) will be mixed with a liquid meal. Liquid meal only: The comparator will be the liquid meal alone.
Study: NCT03382106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 20 MG
Description: Sildenafil, 20mg three times daily for 3 month period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 20 MG
Description: Sildenafil, 20mg three times daily for 3 month period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo manufactured to look like Sildenafil 20 MG
Study: NCT03473691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glembatumumab Vedotin
Description: Standard neo-adjuvant dose-dense doxorubicin 60 mg/m2 and Cytoxan 600 mg/m2 IV every 14 days for 4 cycles followed by GV 1.9 mg/kg IV every 21 days for 4 cycles.
Study: NCT04456816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg AP1189
Description: 100 mg AP1189 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet
Study: NCT03640312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QUARTET LDQT
Description: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan
Description: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.
Study: NCT04762420

Intervention type: OTHER
Intervention: Dose of sugammadex according to SSD and QSD
Description: At the time of pharmacologic reversal of the NMB, both the SSD and QSD, according to portuguese guidelines on the management of the NMB, were recorded. The QSD was then administered to the patient. The SSD was considered appropriate if it was within 10% of the recommended dose for the given depth of NMB, as measured by TOFscan® monitor. The results were analyzed descriptively.

Intervention type: OTHER
Intervention: Dose of sugammadex according to SSD and QSD
Description: At the time of pharmacologic reversal of the NMB, both the SSD and QSD, according to portuguese guidelines on the management of the NMB, were recorded. The QSD was then administered to the patient. The SSD was considered appropriate if it was within 10% of the recommended dose for the given depth of NMB, as measured by TOFscan® monitor. The results were analyzed descriptively.
Study: NCT03157479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous anesthetic
Description: Anaesthesia induction will be obtained with i.v. 2-3 mg/kg propofol, 0,6-0,8 mcg/kg fentanyl, and 0.9-1,2 mg/kg rocuronium. Anaesthesia will be maintained with i.v. propofol continuous infusion, with a dose titrated to achieve a bi-spectral index value between 40 and 50

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid Solutions
Description: Balanced crystalloids will be administered to patients in both groups as a standard rate of 3-5 ml/kg/h. Treatment of eventual hemodynamic instability will be left to the attending physician

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid Solutions
Description: Balanced crystalloids will be administered to patients in both groups as a standard rate of 3-5 ml/kg/h. Treatment of eventual hemodynamic instability will be left to the attending physician

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Esophageal pressure measurement
Description: A nasogastric polyfunctional tube (Nutrivent, Sidam, Italy) will be placed after anaesthesia induction in all enrolled patients to measure esophageal pressure, estimate pleural pressure and compute transpulmonary pressure

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal pressure measurement
Description: A nasogastric polyfunctional tube (Nutrivent, Sidam, Italy) will be placed after anaesthesia induction in all enrolled patients to measure esophageal pressure, estimate pleural pressure and compute transpulmonary pressure

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung volume measurement with the nitrogen washin-washout technique
Description: Lung volume will be measured through nitrogen wash-in wash-out technique and low-flow Pressure-volume curve will be recorded to estimate differences in alveolar recruitment between the two study groups.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lung volume measurement with the nitrogen washin-washout technique
Description: Lung volume will be measured through nitrogen wash-in wash-out technique and low-flow Pressure-volume curve will be recorded to estimate differences in alveolar recruitment between the two study groups.
Study: NCT01214577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 (ingenol mebutate) Gel
Description: 0.015%
Study: NCT01775826

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement
Description: Measured usual (day-to-day) behavior with body-worn sensors.
Study: NCT01898039

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DNP sensititzation
Description: Include brand names, serial numbers and code names, if applicable. Other names are used to improve search results on the ClinicalTrials.gov web site.~On days 1 and 2 patients will be sensitized to DNP by topically applying 0.1 ml of 2% DNP dissolved in acetone-corn oil (Sigma) to the inner aspect of the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: On day 10, intravenous low dose cyclophosphamide, 300 mg/m2, will be administered.
Study: NCT04473248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spartan COVID-19 System
Description: PCR analysis of patient samples using the Spartan COVID-19 System
Study: NCT04070261

Intervention type: OTHER
Intervention: iOS application usability test
Description: user tasks, questionnaires, semi-structured interviews
Study: NCT04473248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spartan COVID-19 System
Description: PCR analysis of patient samples using the Spartan COVID-19 System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spartan COVID-19 System
Description: PCR analysis of patient samples using the Spartan COVID-19 System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spartan COVID-19 System
Description: PCR analysis of patient samples using the Spartan COVID-19 System
Study: NCT04043039

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palatal wound bandage with PRF
Description: palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membranes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palatal wound bandage with PRF
Description: palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membranes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palatal wound bandage with Gelatine Sponge
Description: palatal wound will be protected by gelatine sponge

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palatal wound bandage with Gelatine Sponge
Description: palatal wound will be protected by gelatine sponge
Study: NCT04159246

Intervention type: DEVICE
Intervention: Optical coherence tomography angiography
Description: Recent Optical coherence tomography angiography OCT-A will be performed to all patients before Treatment Administration.~* Examination will be performed using Optovue AngioVue® Optovue, Inc., Fremont, CA, which uses split-spectrum amplitude-decorrelation angiography algorithm, which minimizes motion noise. This system also allows quantitative analysis, since it provides numerical data about flow area and flow density maps.~* The patient will be examined before and after finishing the treatment course

Intervention type: DRUG
Intervention: Sofosbuvir (Sovaldi)
Description: Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C , here it's used with Daclatasvir for 3 months
Study: NCT02038257

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MKTP (melanocyte keratinocyte transplant procedure)
Description: Each subject will have the melanocyte keratinocyte transplant procedure on 4 distinct areas using the two different techniques being studied (carbon dioxide laser and dermabrasion) and the two different dressings being studied (vaseline impregnated gauze and collagen dressing).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MKTP (melanocyte keratinocyte transplant procedure)
Description: Each subject will have the melanocyte keratinocyte transplant procedure on 4 distinct areas using the two different techniques being studied (carbon dioxide laser and dermabrasion) and the two different dressings being studied (vaseline impregnated gauze and collagen dressing).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MKTP (melanocyte keratinocyte transplant procedure)
Description: Each subject will have the melanocyte keratinocyte transplant procedure on 4 distinct areas using the two different techniques being studied (carbon dioxide laser and dermabrasion) and the two different dressings being studied (vaseline impregnated gauze and collagen dressing).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MKTP (melanocyte keratinocyte transplant procedure)
Description: Each subject will have the melanocyte keratinocyte transplant procedure on 4 distinct areas using the two different techniques being studied (carbon dioxide laser and dermabrasion) and the two different dressings being studied (vaseline impregnated gauze and collagen dressing).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen Dressing
Description: Each subject will have MKTP on 4 distinct areas. Two of these areas will be dressed with a collagen dressing.
Study: NCT01683825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 florbetapir PET
Description: Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 florbetapir PET
Description: Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid)

Intervention type: DRUG
Group type: OTHER
Intervention: F-18 florbetapir PET
Description: Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid)
Study: NCT01528189

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperinsulinemic normoglycemic clamp
Description: Patients will receive an IV infusion of 2 mU/kg/min (0.12 U/kg/hour) starting in the operating room. Dextrose 20% will be titrated to maintain blood glucose between 4 and 6 mmol/l. At the end of surgery, the insulin infusion will be stopped and the dextrose infusion weaned off in the postanesthesia care unit.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard glucose management
Description: Blood glucose levels will be treated by a standard insulin sliding scale.
Study: NCT04116073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCMGA00012 (PD-1 antibody)
Description: 1. Treatment of INCMGA00012 will be administered every 4 weeks (28 days) while patient is on study. Intravenous administration of INCMGA00012 (500 mg) will occur on Day 1 of each 28 day cycle.~2. Drug: 500 mg is to be administered as a 30 minute IV infusion (-5/+15 min)
Study: NCT01122693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eZono - high-quality 2D ultrasound images
Description: higher ultrasound frequencies, better image resolution, better post-processing and user-friendliness.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: eZono - high-quality 2D ultrasound images
Description: higher ultrasound frequencies, better image resolution, better post-processing and user-friendliness.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: eZono - high-quality 2D ultrasound images
Description: higher ultrasound frequencies, better image resolution, better post-processing and user-friendliness.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard 2D ultrasound images
Description: current standard in two-dimensional (2D) ultrasound images

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard 2D ultrasound images
Description: current standard in two-dimensional (2D) ultrasound images

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard 2D ultrasound images
Description: current standard in two-dimensional (2D) ultrasound images
Study: NCT00550966

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducative program in fibromyalgic patients
Description: Multi-component program including information about the illness, counselling about physical exercise and training in autogenic relaxation. The intervention consists on nine 2 hour sessions delivered during a two month period. The pharmacological treatment prescribed by the physician is maintained in both groups.
Study: NCT02596789

Intervention type: DEVICE
Group type: OTHER
Intervention: TMS Magpro®, Magventure Inc device